September 23, 2019
FDA: Class I recall of Allergan Natrelle Biocell textured breast implants
Editor's Note
The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.
The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.
Distribution dates are September 14, 2014, to July 24, 2019.
Free Daily News
- HHS releases concept paper on cybersecurity for healthcare sector
- Study examines infection precautions during pandemic based on healthcare roles
- Postoperative opioid prescriptions falling, but more improvement needed
- New protein calculation uncovers which organs are aging at an accelerated pace
- Researchers are calling for better tracking of chronic diseases
- New Joint Commission certification addresses secondary use of data
- New wearable device system could aid in remote medical monitoring
- Looking more closely at nurse burnout, impact on quality care
- FDA issues safety notice for syringes made in China
- Online training program significantly reduces postop complications following colon surgery
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging